



HORIZON

Horizon at a Glance



More than
1,000 employees



A primary focus on rare
patient populations



11 medicines that treat rare
and rheumatic conditions




Personally invested in
our patients wherever
they are in their journey




Corporate headquarters in Dublin,
Ireland, with U.S. operations
in Lake Forest, Illinois

We are Bringing Forward Medicines That Address Unmet Needs in Both Rare and Rheumatic Disease




RARE DISEASE

Urea Cycle Disorder, Cystinosis, Chronic Granulomatous Disease, Severe Malignant Osteopetrosis, Thyroid Eye Disease




RHEUMATIC DISEASE


Osteoarthritis, Rheumatoid Arthritis, Polymyalgia Rheumatica, Ankylosing Spondylitis, Uncontrolled Gout



Out of 11 medicines for the treatment of **RARE DISEASES**



New clinical research programs for **DEVELOPMENT STAGE MEDICINES**



Research programs **EXPLORE THE FURTHER USE OF OUR CURRENT MEDICINES**

Building a Robust Rare Disease Pipeline

MEDICINE / PROGRAM	DESCRIPTION	PRE-CLINICAL	PHASE 1	PHASE 2	PHASE 3	PHASE 3b / 4
KRYSTEXXA®	<ul style="list-style-type: none"> MIRROR immunomodulation study: KRYSTEXXA + methotrexate⁽¹⁾ ●				
KRYSTEXXA	<ul style="list-style-type: none"> Study in kidney transplant patients with uncontrolled gout⁽²⁾ ●				
HZN-001 (teprotumumab) ⁽³⁾	<ul style="list-style-type: none"> OPTIC trial: Phase 3 (complete) OPTIC-X trial: Phase 3 extension ●		●	
HZN-003	<ul style="list-style-type: none"> Optimized uricase and optimized PEGylation for uncontrolled gout ●				
HZN-007 ⁽⁴⁾	<ul style="list-style-type: none"> Optimized uricase and PASylation for uncontrolled gout ●				
HemoShear Gout Discovery Collaboration	<ul style="list-style-type: none"> Exploration of novel approaches to treating gout ●				

(1) Planned study, expected to begin in June.

(2) Planned study, expected to begin in the second half of 2019.

(3) Teprotumumab is a fully human monoclonal antibody (mAb) IGF-1R inhibitor in development for active thyroid eye disease (TED).

(4) Being developed under a collaboration agreement.

MIRROR: **M**ethotrexate to **I**ncrease **R**esponse **R**ates in Patients with Uncontrolled **G**Out Receiving KRYSTEXXA.

OPTIC: Treatment of Graves' **O**rbitopathy (Thyroid Eye Disease) to Reduce **P**roptosis with **T**eprotumumab Infusions in a Randomized, Placebo-Controlled, Clinical Study.

Teprotumumab is an investigational candidate and its safety and efficacy have not been established.



Heart of Horizon: Commitment Beyond Our Medicines

#RARE is...



We Participate, Listen and Learn with Our Disease Communities



+50



+1,000





Patient advocacy group partnerships globally

Employees take part in hundreds of advocacy events around the world



We Create Change in Our Community: Annual Impact





“Going above and beyond for patients is what we do every day. It is at the core of our company culture and reflects my own experience as a patient.”

Timothy Walbert

Chairman, President and CEO

Working At Horizon Isn't Just A Job. For Me, It's Personal.



Thank you